The medtech industry is at a crossroads.
More people, longer life spans, and the COVID-era health wake-up call gave the sector a big push. While it saw sustained growth over the last three years, the rising revenues (about 3.7% per year since 2021) are not adding up.
Making profits is getting harder. But why?
Because costs are ballooning faster than sales. And that’s just one of the challenges medtech companies are grappling with in 2025.
So what should medtech companies focus on right now to stay ahead?
In a deep-dive analysis of 100 medtech companies by Porsche Consulting, Dr. Roman Hipp, partner and medtech lead, outlined four clear priorities for companies that want to stay competitive and profitable.
Here’s the breakdown.
What’s happening in medtech right now?
US companies continue to dominate the global medtech sector, while European competitors struggle to stay up. Only a few European corporations have achieved higher profits before interest and taxes (EBIT).
While revenues are up, profit margins are thinning, due to rising operational and regulatory costs.
Health systems globally are under pressure to reduce spending, which trickles down to pricing pressure for medtech suppliers.
Geopolitical tensions and shifting trade dynamics are disrupting supply chains and market access.
Meanwhile, digital transformation and AI integration—buzzwords for years—are now mission-critical but under-delivered.
“The medtech industry is at a crossroads. Successful companies will be those that take bold steps to rethink how they innovate, manufacture, digitalise, and attract talent,” says Dr. Roman Hipp.
Four game-changing strategies for 2025
Let’s cut through the jargon.
Dr Roman Hipp, who oversees the pharma and medtech sectors at Porsche Consulting, suggests four strategic imperatives for companies seeking to outperform competitors in 2025.
Here’s what MedTech leaders really need to do this year:
#1 Reinventing the innovation process
Speed has become the new competitive edge in medtech. The decade-long product cycles won’t cut it anymore.
Healthtech startups and IT companies are launching connected, AI-powered devices at lightning speed. Traditional MedTech needs to keep up.
“Speed is the new currency of innovation,” notes Dr. Hipp. “Companies that master shorter development cycles will win.”
What to do:
- Think software-first. Build full patient-care systems, not just devices.
- Design smarter, connected products that are future-proof for digital health systems.
- Use virtual prototyping to reduce costly delays.
- Adopt agile development and software-driven methods from the tech world.
#2 Building resilient, efficient supply networks
Many medtech companies have grown through acquisitions but failed to integrate their manufacturing operations or supply networks effectively. As a result, they have a fragmented global footprint with missed opportunities.
“Increased regulatory scrutiny and geopolitical shifts make supply chain strategy a boardroom issue,” says Dr. Hipp.
Key steps:
- Consolidate operations for efficiency and flexibility.
- Build strategic manufacturing bases in key markets, like the US and select APAC countries (India, China, Japan, South Korea).
- Localise where needed, especially in response to rising protectionism.
- Tighten quality management. FDA inspections of foreign firms jumped 243%, mostly for quality system violations.
Leading companies are responding by creating globally harmonised standard operating procedures while deploying digital tools that make quality an integral part of every process.
#3 Getting serious with digital initiatives
Most medtech firms are still scratching the surface of digital transformation. Despite all the hype, two-thirds of the largest players make just 0–10% of revenue from digital initiatives.
“Digitalisation is no longer a nice-to-have; it’s essential to driving productivity, connectivity, and patient outcomes,” Dr. Hipp emphasises.
Three 2025 must-dos:
- AI at scale: Targeted AI programs can cut costs by up to 20% and boost efficiency by 30–40% in key areas like marketing and sales.
- Software as a Medical Device (SaMD): This $700 bn opportunity is growing fast, but traditional players hold just 27% of FDA authorisations.
- Partnerships: Modern devices are software-heavy with over 15 mn lines of code in imaging equipment. No one can go it alone. Partnering is essential.
#4 Winning the talent war: Your people will make or break you
Talent shortages are a growing crisis. Finding the right people is one of the most difficult yet frequently neglected difficulties facing medtech organisations.
In the past five years, the demand for experienced professionals in the industry has grown by 30%. But, the talent pool is shrinking, expected to shrink by 7% by 2030.
“People are the ultimate differentiator,” says Dr. Hipp. “Companies that offer purpose, growth, and security will win in the long run.”
To stand out:
- Sell the purpose. Healthcare makes a real impact.
- Offer clear career paths, especially in tech-forward roles.
- Create roles that excite the next-gen workforce, like AI, robotics, digital health.
- Ensure job security and competitive pay.
Bottom line: 2025 is a turning point
The medtech industry in 2025 is being reshaped by complex pressures. Economic, digital, geopolitical, and human. But with the right moves, there’s massive opportunity.
Companies that speed up innovation, restructure for agility, embrace digital fully, and invest in people are likely to lead the next wave of medtech growth.
As Dr. Hipp puts it:
“The fundamentals are solid. It’s the execution—fast, bold, and strategic—that will define the next medtech leaders.”
-By Alkama Sohail and the AHT Team
